Brainstorm Cell Therapeutics Adds Shares to Equity Incentive Plan

Brainstorm Cell Therapeutics ( (BCLI) ) just unveiled an announcement.

On February 24, 2026, Brainstorm Cell Therapeutics Inc. entered into a $1 million private placement with an accredited investor, structured in up to eight closings, selling common stock and pre-funded warrants at about $0.60 per share equivalent. The deal also includes common stock purchase warrants exercisable at $1.00 per share, with the first $125,000 closing completed on February 24, 2026, and remaining closings of up to $875,000 scheduled at the investor’s discretion by September 25, 2026.

The company committed to register the resale of the securities, maintain the stock’s exchange listing and use the net proceeds for working capital, reinforcing liquidity without a public offering. On February 26, 2026, the board approved amendments to its 2014 equity plans to add 5.5 million shares to the shared award pool, expanding it to 8,406,666 shares and increasing the capacity to grant stock-based incentives to officers, directors and other eligible participants.

These financing and equity plan moves signal Brainstorm Cell Therapeutics’ continued reliance on dilutive capital raising and equity compensation as it funds operations and seeks to retain key personnel. The structure, including ownership limits and warrant coverage, reflects an effort to balance investor demand, regulatory compliance and trading market requirements while potentially impacting existing shareholder dilution and governance dynamics.

The most recent analyst rating on (BCLI) stock is a Hold with a $0.61 price target. To see the full list of analyst forecasts on Brainstorm Cell Therapeutics stock, see the BCLI Stock Forecast page.

Spark’s Take on BCLI Stock

According to Spark, TipRanks’ AI Analyst, BCLI is a Neutral.

Overall score is held down mainly by weak financial performance (large operating losses, ongoing cash burn, and equity/funding risk). Technicals are also soft with the stock below key longer-term averages. Corporate events add some support via new financing and development progress, but carry dilution/financing risk, and valuation remains constrained by negative earnings and no dividend.

To see Spark’s full report on BCLI stock, click here.

More about Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc. operates in the biotechnology sector, focusing on the development of cell-based therapies, with its common stock listed on a public trading market. The company utilizes equity financing tools, including common stock, pre-funded warrants and stock incentive plans, to support working capital needs and align employee and director compensation with shareholder interests.

Average Trading Volume: 23,923

Technical Sentiment Signal: Sell

Current Market Cap: $7.34M

Learn more about BCLI stock on TipRanks’ Stock Analysis page.